The popularity of Sildenafil initially fueled a period of growth for major pharmaceutical companies, but recent shifts present a murky picture for those considering a stake. Generic versions are eating into profits, https://arunlcbd062354.blogpostie.com/62393737/the-blue-pill-and-big-pharma-a-volatile-play